Clinical Trial Update: A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity data were collected for three doses of Opal Immunotherapy in people with HIV infection, but the study was terminated. The tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Opal Immunotherapy

Snippet

Sponsor: Medicines Development for Global Health | Conditions: HIV Infections | Phase 1 | Status: TERMINATED